SGLT-2抑制剂联合RAASi治疗糖尿病肾病的研究进展(4)
[9] Wanner C，Inzucchi SE，Lachin JM，et al.Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med，2016，375(4)：323-334.[10] Mahaffey KW，Jardine MJ，Bompoint S，et al.Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups[J].Circulation ......
您现在查看是摘要页，全文长 2573 字符。